Company intelligence / Profile preview
Ningbo Xijian Pharmaceutical Technology Co., Ltd.
- Ownership
- Private
- Development stage
- Preclinical
Overview
Ningbo Xijian Pharmaceutical Technology is developing EG017, a selective androgen receptor modulator intended to treat stress urinary incontinence and other conditions related to androgen deficiency in middle-aged and elderly populations. The company has conducted multiple clinical trials, including a multicenter, randomized, double-blind Phase IIb study for stress urinary incontinence. Some of these studies have been terminated or completed as of early 2025. No approved products are reported.
- Therapeutic areas
- OphthalmologyWomen's Health
- Modalities
- Small molecules (specifically selective androgen receptor modulators, SARMs)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Ningbo Xijian Pharmaceutical Technology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ningbo Xijian Pharmaceutical Technology Co., Ltd..